(Q38054948)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23092694%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Antiepileptic drug effects on mood and behavior: molecular targets (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23092694%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23092694%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Marco Mula

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23092694%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Piero Perucca

series ordinal

1

1 reference

27 August 2017

Marco Mula

series ordinal

2

1 reference

27 August 2017

publication date

23 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23092694%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23092694%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23092694%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23092694%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

440-449

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23092694%20AND%20SRC:MED&resulttype=core&format=json

New antiepileptic drugs: molecular targets

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Pharmacological management of epilepsy: recent advances and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Psychotropic effects of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Negative effects of antiepileptic drugs on mood in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Neuropsychological and behavioral effects of antiepilepsy drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Depression following withdrawal from long-term benzodiazepine use: a report of four cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

GABA and glutamate systems as therapeutic targets in depression and mood disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Alterations in the N-methyl-d-asparatate (NMDA) receptor complex in the frontal cortex of suicide victims

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Stress-induced changes in messenger RNA levels of N-methyl-D-aspartate and AMPA receptor subunits in selected regions of the rat hippocampus and hypothalamus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Plasma and platelet excitatory amino acids in psychiatric disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Neuropathology of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Changes in Erythrocyte Sodium and Potassium on Recovery from a Depressive Illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Mood stabilizers and ion regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test; antidepressants facilitate nifedipine action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Blockade of intracellular calcium release induces an antidepressant-like effect in the mouse forced swimming test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Isoform-specific regulation of mood behavior and pancreatic β cell and cardiovascular function by L-type Ca2+ channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ α2δ-1 subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The serotonin transporter: a primary target for antidepressant drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Major depressive disorder: new clinical, neurobiological, and treatment perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Biphasic effects of zonisamide on serotonergic system in rat hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The role of dopamine in mood disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

7 January 2021

Dopamine and depression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Valproate and its major metabolite E-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Effects of zonisamide on dopaminergic system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Anticonvulsants in bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Psychic disorders in epilepsy. Clinical and electroencephalographic research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Forced normalization: clinical and therapeutic relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Primidone is associated with interictal depression in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Phenytoin as an antimanic anticonvulsant: a controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Prophylactic effect of phenytoin in bipolar disorder: a controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

A comparison of anticonvulsants in the treatment of impulsive aggression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Choreo-athetosis and encephalopathy induced by phenytoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Psychiatric syndromes related to antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Psychotic Episodes in Zarondan Treatment Effects and Side‐effects in 105 Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Maintenance efficacy of divalproex in the prevention of bipolar depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Psychiatric adverse events during vigabatrin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Psychotic and severe behavioural reactions with vigabatrin: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Vigabatrin and behaviour disorders: a retrospective survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Is adjunctive open-label zonisamide effective for bipolar disorder?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Enhancement of brain kynurenic acid production by anticonvulsants--novel mechanism of antiepileptic activity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Clinical practice. Bipolar disorder--a focus on depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Effect of lamotrigine on depressive symptoms in adult patients with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Behavioural effects of the newer antiepileptic drugs: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Felbamate Monotherapy: Implications for Antiepileptic Drug Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Treatment of social phobia with gabapentin: a placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Gabapentin toxicity in children manifesting as behavioral changes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Behavioral side effects of gabapentin in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Topiramate and psychiatric adverse events in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The role of titration schedule of topiramate for the development of depression in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Treatment of obese patients with binge eating disorder using topiramate: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Psychopharmacology of topiramate: from epilepsy to bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Effects of tiagabine monotherapy on abilities, adjustment, and mood.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Tiagabine in treatment refractory bipolar disorder: a clinical case series.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Tiagabine: The Safety Landscape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Antiepileptic drugs and psychopathology of epilepsy: an update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Potential of levetiracetam in mood disorders: a preliminary review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Levetiracetam in social phobia: a placebo controlled pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Psychiatric adverse events during levetiracetam therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Discontinuation of levetiracetam because of behavioral side effects: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The effects of stiripentol on GABA(A) receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Stiripentol open study in Japanese patients with Dravet syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Augmentation with pregabalin in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Pregabalin in the treatment of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The possible antianxiety and mood-stabilizing effects of rufinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Novel medications for epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Adverse effects of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Interpreting regulatory trials in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018

Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2012.09.018